Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Mesulergine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.47 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 6/20 | 0.96 |
| ▸ | HTR2A | P28223 | 4/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | HTR7 | P34969 | 3/20 | 0.96 |
| ▸ | HTR1A | P08908 | 3/20 | 0.96 |
| ▸ | HTR2C | P28335 | 3/20 | 0.96 |
| ▸ | HTR6 | P50406 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.64 |
| ▸ | RGS12 | O14924 | 3/20 | 0.64 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.63 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mesulergine SCHEMBL29408582 | 0.98 | HTR2B (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL3143855 | 0.98 | HTR2B (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL292175 | 0.98 | HTR2B (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL11415354 | 0.98 | HTR2B (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Mesulergine SCHEMBL1321023 | 0.97 | HTR2B (0.98) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| SCHEMBL10670412 | 0.86 | HTR2B (0.78) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| SCHEMBL10670405 | 0.86 | HTR2B (0.78) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| SCHEMBL10670418 | 0.86 | HTR2B (0.78) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Disulergine SCHEMBL11408974 | 0.79 | HTR7 (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A | |
| Disulergine SCHEMBL11408971 | 0.79 | HTR7 (1.00) | HTR2BHTR2AALDH1A1HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | disclosed |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | TERRAN BIOSCIENCES, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigacions Cientificas (CSIS) (ES) | 2020-12-24 | — | — | US | disclosed |
| EP-3713568-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-09-30 | — | — | EP | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| EP-2288345-B1 | PSYCHO-PHARMACEUTICALS | UNIV DUBLIN (IE) | 2015-06-10 | — | — | EP | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | CHRM2 326/4885CHRM1 614/4885ACHE 548/4885 |
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | CHRM2 563/4885CHRM1 755/4885ACHE 259/4885 |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | CHRM2 566/4885CHRM1 648/4885ACHE 321/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | CHRM2 985/4885CHRM1 1980/4885ACHE 712/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | CHRM2 287/4885CHRM1 814/4885ACHE 47/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | CHRM2 563/4885CHRM1 755/4885ACHE 259/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | CHRM2 65/4885CHRM1 153/4885ACHE 40/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | CHRM2 15/4885CHRM1 24/4885ACHE 18/4885 |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | HTR2A, HTR2C, HTR1A | CHRM2 563/4885CHRM1 755/4885ACHE 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.